FARSB: A Potential Drug Target and Biomarker (G10056)

Target Name: FARSB

NCBI ID: G10056

FARSB

FARSB: A Potential Drug Target and Biomarker

FARSB (Farnesyl-伪-riboside), a sialic acid found in many human tissues, has been identified as a potential drug target and biomarker for various diseases. This derivative of riboside A, which is found in most cell types, has been shown to play a crucial role in various cellular processes, including cell signaling, DNA replication, and protein synthesis.

The identification of FARSB as a potential drug target comes from its ability to modulate cellular signaling pathways, particularly those involved in cell survival and proliferation. Studies have shown that FARSB can inhibit the negative signaling effects of various oncogens, such as reactive oxygen species (ROS) and DNA damage, leading to increased cell survival and proliferation.

FARSB has also been shown to play a key role in the regulation of cellular apoptosis, which is the process by which cells undergo programmed cell death. FARSB has been shown to induce cell apoptosis in various cell types, including cancer cells, leading to a potential mechanism of cancer treatment.

In addition to its potential drug target properties, FARSB has also been identified as a potential biomarker for various diseases. The ability to modulate cellular signaling pathways makes it an attractive tool for the development of diagnostic tests for certain diseases. For example, FARSB has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that FARSB may be a useful biomarker for the diagnosis and treatment of these diseases.

FARSB's potential as a drug target and biomarker is of particular interest because it has been shown to be involved in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive target for the development of new treatments for these diseases.

In addition to its potential drug and biomarker properties, FARSB also has important structural features that make it a unique compound. FARSB is a sialic acid, which is a type of sugar that is found in many human tissues and is involved in the development of various diseases, including cancer. The sweet taste of FARSB has made it an attractive compound for the development of pharmaceuticals with novel chemical structures.

FARSB has also been shown to have unique physical properties that make it an attractive target for drug development. FARSB is a hydrophobic compound, which means that it is not soluble in water and has a low water solubility. This makes it an attractive target for the development of compounds that are able to selectively bind to FARSB and are not excreted by the kidneys.

In conclusion, FARSB is a promising compound that has the potential to be a drug target and biomarker for a wide range of diseases. Its ability to modulate cellular signaling pathways and its potential as a biomarker make it an attractive target for the development of new treatments. Its unique physical properties, including its hydrophobicity, also make it an attractive target for the development of compounds that are able to selectively bind to FARSB. Further research is needed to fully understand the potential of FARSB as a drug target and biomarker.

Protein Name: Phenylalanyl-tRNA Synthetase Subunit Beta

The "FARSB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FARSB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets